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Introduction
If only there were a magic bullet that could eliminate
the Helicobacter pylori bacterium without any patient
side effects and be given at a low cost, there would be
no need to give anti–H pylori therapy to specific patient
groups. We could simply treat everyone. Since the
discovery of this organism in 1983,1 evidence has
accumulated that confirms its association with certain
upper gastro-intestinal tract disorders. However, there
are other conditions for which only tenuous evidence
is available to support its aetiopathogenetic role. This
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article reviews the current evidence using the Sackett
scoring system2 (Table 1) to establish in which patients
anti–H pylori therapy should be imperative or beneficial
and which patients who should not be treated.
Natural history of H pylori infection
In a study of native American children, Perez-Perez
et al3 showed that once contracted, H pylori infect-
ion remains lifelong in the majority of infected
individuals. Circulating immunoglobulin (Ig) G and
IgM anti–H pylori antibodies are unable to defend
the gastro-duodenal mucosa from the toxic effects of
H pylori. As a direct or indirect result of this organism,
different pathological entities evolve that result in
clinical disorders. Some disorders have a significant
impact on health and require intervention. However,
most infected individuals remain asymptomatic and
clinically disease-free. Guidelines have been estab-
lished recently in North America,4 Europe,5 and the
Asia-Pacific region6; they outline when antibacterial
agents should be used to eliminate H pylori infection
in different gastroduodenal disease subgroups. On
the other hand, those who are H pylori–positive
asymptomatic carriers should not be treated except
under special circumstances.
Table 1. Sackett grading scale for ranking the reliability of clini-
cal trial results2
Grade Definition
A Large, randomised controlled trial
B Small, non-definitive randomised trial
C Non-randomised study
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H pylori infection and associated pathological
changes
Correa7 performed a cross-sectional and longitudinal
follow-up study in Columbia and found that the pre-
valence of infection was high, at around 80% of the
population. Subsequent surveillance of the participants
and evaluation of the histopathological features of
their gastric biopsies enabled the investigators to
construct a hierarchy of pathological changes over a
decade in the untreated, infected individuals.7 It was
found that H pylori infection continued to colonise
the stomach and triggered the development of acute
gastritis and then chronic superficial gastritis. In a
proportion of the subjects chronic atrophic gastritis
developed, with or without intestinal metaplasia,
dysplasia, or carcinoma changes.
Numerous cross-sectional, case-control studies
have demonstrated that H pylori infection is associated
with an increased incidence of gastric carcinoma.8-12
The best evidence for this comes from a number of
longitudinal studies.8-10 The overall increased risk
has been estimated to be up to six times that of non-
infected individuals. Studies from Scandinavia reveal
that H pylori infection also increases the risk of peptic
ulceration by five- to 15-fold after a mean follow-
up period of 10 years.13,14 It is still unclear whether
H pylori has a significant clinical role in patients
with functional dyspepsia, also commonly known as
non-ulcer dyspepsia (NUD).
When is H pylori eradication therapy indicated?
H pylori and peptic ulcer disease
Approximately one in 10 adults develops peptic
ulceration in their lifetime.15 It is well known that
peptic ulcers that are not induced by non-steroidal
anti-inflammatory drugs (NSAIDs) or acute stress
have a tendency to recur. Acid suppressor or mucosal
protective agents have been used to prevent recurrence
of peptic ulceration and peptic ulcer bleeding. How-
ever, it has been shown that peptic ulcer recurrence
and bleeding still occur in 10% to 20% of individuals
despite long-term maintenance therapy. Since docu-
mentation of the role of H pylori in peptic ulcer disease,
therapeutic clinical trials have been conducted to
evaluate the long-term outcome of eradication therapy
in these patients. It has been demonstrated that not only
do ulcers (duodenal or gastric) heal after the successful
elimination of the organism, but also the relapse rate
significantly reduces to approximately 6%.16,17 A recent
meta-analysis of all the well-conducted trials per-
formed in the United States by Laine et al18 has detected
a 20% recurrence rate of peptic ulceration, rather than
the reported rate of approximately 6%. In addition, the
study confirmed that those who remain infected with
H pylori have a five-fold increased risk of having a
recurrence of peptic ulceration compared with those
in whom H pylori is successfully eradicated. Patients
who have had ulcer bleeding also have a significantly
lower rate of relapse and recurrent bleeding when the
organism has been cleared.19-21
Expert panels have recommended H pylori–positive
patients with ulceration should have H pylori eradi-
cation therapy (Table 2).4-6 The decision was based on
numerous level-I randomised controlled trials that
demonstrated beneficial effects.22-27 Maintaining acid
suppression after successful H pylori eradication
therapy, even in those who have had prior bleeding
or perforated ulcers, is now considered unnecessary.
A recent randomised study by Maier et al28 reported
no recurrent bleeding in the H pylori eradication
therapy group compared with a 12% rebleeding rate
in the ranitidine maintenance therapy (H pylori–
infected) group within 1 year of follow-up.
It has been repeatedly demonstrated that H pylori
eradication therapy is significantly more cost-effective
than either on-demand or maintenance acid suppression
therapy for H pylori–infected patients who have a
history of previous or current peptic ulcer disease.29-31
The development of mucosa-associated lymphoid
tissue–type lymphoma
Gastric mucosa-associated lymphoid tissue (MALT)–
Table 2. H pylori eradication therapy recommendations for various gastroduodenal disease subgroups4-6
Gastroduodenal disease Recommendation Sackett grades
Peptic ulcer disease (active or past history) Imperative A
Peptic ulcer bleeding (active or past history) Imperative A
Low-grade gastric MALT* lymphoma Imperative C
Gastritis with severe unresponsive NUD† Worth a trial C
Following complete resection of gastric cancer Worth a trial C
Previous ulcer history requiring NSAIDs‡ Worth treating C
* MALT mucosa-associated lymphoid tissue
†
 NUD non-ulcer dyspepsia
‡
 NSAIDs non-steroidal anti-inflammatory drugs
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type lymphoma has been shown to be strongly
associated with H pylori infection.32 Accordingly,
successful eradication of the organism has been
proven to cure the majority of cases of early-grade
gastric MALT lymphoma.33-35 Hence, patients with
the latter condition should be treated with the appro-
priate H pylori eradication therapy and given appro-
priate follow-up to assess whether the eradication
and elimination of the lymphoma cells has been
successful (Table 2).4-6 Higher-grade gastric MALT
lymphomas, however, should receive additional
therapy, since the majority cannot be cured by H pylori
eradication therapy alone.
Patients in whom the eradication of H pylori
can be beneficial (Table 2)
H pylori infection and non-ulcer dyspepsia
This is a grey area and no consensus agreement on
the value of eradication of H pylori infection exists. A
recent survey of gastro-enterologists in the United
Kingdom revealed that the majority (69%) would
advocate a trial of H pylori eradication therapy in
patients with NUD despite the fact that 75% of the
specialists disagreed that there was a relationship
between the two.36 Epidemiological evidence sup-
ports the view that H pylori infection and NUD are
linked.37 Therapeutic trials have been criticised for
being flawed, which thus has affected the significance
of the studies.38 However, recent studies in the United
States39 and Taiwan40 confirm that the successful
eradication of H pylori infection leads to a significant
reduction in NUD symptom scores.
Until further guidelines are available, it has been
suggested that each case should be considered
separately as to whether or not H pylori eradication
therapy should be instituted. We consider that those
who have had long-standing persistent or recurrent
NUD symptoms that have not responded to conven-
tional symptomatic therapy, should be given the
benefit of such therapy. This approach was also
endorsed by the panel of experts who met at the 1998
Asian-Pacific consensus meeting.41 Although there
is very little evidence that eradication of H pylori
alters the underlying motility disorder, some patients
may derive symptomatic improvement. Our own
experience shows that the majority of these patients
obtain significant symptomatic relief, although the
improvements last for less than 6 months only (un-
published data). Approximately 60% of the patients
did not require further medication. Of the balance,
most patients required fewer medications to control
their NUD symptoms.
H pylori eradication therapy and early gastric can-
cer recurrence
Japan is one of the leading countries with a high an-
nual gastric cancer mortality rate. Consequently, mass
screening is a common practice for those who are older
than 40 years. As a result, early gastric cancers are
regularly detected in a subgroup who are thus spared
the need to undergo a formal gastrectomy. Instead,
mucosectomy has been used to cure these patients.
Adjunctive H pylori eradication therapy after muco-
sectomy reduces the recurrence of gastric cancer in
patients in whom the organism has been successfully
eradicated,42 compared with those who have a muco-
sectomy only. Unfortunately, mass gastric cancer
screening has not been proven useful or practical out-
side of Japan, where the incidence is high. Because
gastric cancer is usually diagnosed at a late stage of
disease, performing a mucosectomy is not a valid
therapeutic option. Studies, however, have begun to
see if the successful elimination of H pylori has any
beneficial outcome in terms of survival after gastric
cancer resection. The results of these studies are
eagerly awaited.
Non-steroidal anti-inflammatory drugs, peptic
ulcers, and H pylori infection
One of the main causes of ulceration in the stomach
and the duodenum is the taking of NSAIDs. At the
recent Asia-Pacific consensus meeting,6 the possible
additive harmful effect of NSAIDs and H pylori
infection were discussed. It was unanimously agreed
that routine testing for and treatment of H pylori
infection is not to be recommended prior to initiating
NSAID therapy. Recent preliminary therapeutic
studies, however, demonstrate that by rendering
patients H pylori–negative, there is a significantly
lower risk of new or recurrent peptic ulceration and
bleeding in patients who use NSAIDs.43,44 On the
other hand, the value of eliminating H pylori has
also been challenged by others who have shown that
H pylori and NSAIDs act negatively rather than
synergistically to reduce peptic ulcer bleeding.45
It is generally accepted that patients who have a
history of peptic ulcer, with or without bleeding, should
be tested for H pylori infection. If the presence of the
bacterium is confirmed, patients should be treated
accordingly before NSAIDs are given. The Asia-Pacific
Consensus Panel6 decided that patients who require
lifelong maintenance NSAID therapy should be tested
and treated for H pylori infection if they have recent
or current dyspepsia. Alternatively, these patients could
be given lifelong treatment with omeprazole, which
has been shown to be superior to both ranitidine or
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misoprostol in healing and preventing the development
of NSAID-induced peptic ulcers.46,47 Lately, alterna-
tive NSAIDs, the cyclo-oxygenase (COX)-2 inhibitors,
have become available. They are less likely to cause
gastro-intestinal adverse effects when compared with
the conventional NSAIDs, which are COX-1 inhibitors.
It is not yet known if eradication therapy is beneficial
for patients who are taking the COX-2 inhibitors.
Other conditions that might benefit from the
eradication of H pylori
Treating those with premalignant gastric lesions
It has been suggested that premalignant gastric lesions
such as dysplasia and intestinal dysplasia may be
reversed after H pylori eradication therapy.48,49 This is
a very controversial area and many experts are sceptical
that these results can be achieved.50
It is known that premalignant gastric lesions are
associated with chronic H pylori infection. These
lesions have also been shown to be linked to the
gastric cancer prevalence in various regions of the
world.51 Hence, it is thought that H pylori plays a
vital aetio-pathogenetic role in the malignant trans-
formation of cells in the stomach. Thus, the World
Health Organization has categorised H pylori as a
class-I carcinogen.52 Definitive proof of the relation-
ship between H pylori infection and the development
of gastric premalignant and malignant lesions will
have to come from the results of current interventional
studies in Japan and China. Until it can be shown
that the prevalence of gastric premalignant and
malignant lesions can be either halted and/or reduced
by the successful eradication of H pylori from
people living in areas with a high incidence of
gastric cancer, such as Japan and certain provinces of
China, it is inappropriate to treat all infected patients
on the grounds that they may one day develop gastric
cancer.
Family members of gastric cancer patients may be
offered H pylori testing and appropriate treatment if
they wish, but screening for H pylori infection in such
individuals should not be recommended.
Should cagA–positive H pylori be eliminated?
Helicobacter pylori strains that bear the cytotoxin
VacA and its associated cagA genes are with signifi-
cant gastrodudoenal pathologies such as peptic ulcer,
gastric cancer, and NUD. The presence of these
pathogenic strains can now be readily detected by a
serological assay53 instead of the more tedious poly-
merase chain reaction techniques. Unfortunately, the
majority (approximately 70%) of H pylori strains in
south-east Asia are cagA-positive, which makes it
difficult to distinguish the subgroups with disease
from those who are asymptomatic carriers by using
the serological assay alone. In a recent study, we demon-
strated that more than 50% of symptomatic patients,
were cagA-positive, but about 25% of the asympto-
matic patients carried the same gene.53 If we were
to screen symptomatic patients with the anti-cagA
assay and target therapy to those who were positive,
we would only miss a small percentage of patients
with ulcers (<10%) and approximately 50% of NUD
patients. Whether treatment should be given to the
latter patients is still undecided at this stage. If we
take the extreme view that all H pylori–infected NUD
patients should be treated, we will have undertreated
half of these patients. On the other hand, if none of
them should be treated, we will have overtreated half
of these patients. Further studies are still required to
help clinicians selectively target treatment towards
those who most need it.
Patients in whom H pylori eradication therapy is
not indicated
Helicobacter pylori has been incriminated as one
of the possible aetiological factors in a variety of
clinical diseases outside of the digestive system—
for example, short stature in children, coronary artery
disease, and autoimmune disease.54 The evidence
for such claims is weak and the link often is not
substantiated by further studies. These patients should
not be treated with H pylori eradication therapy if
they do not have any history of peptic ulcer disease
or significant NUD symptoms. Likewise, healthy,
asymptomatic individuals and their relatives should
not be treated or even tested for H pylori infection.
However, there are exceptions because recent prelimi-
nary evidence suggests that spouses of H pylori–
positive patients, particularly those who are symp-
tomatic, are at significantly greater risk of being
infected by the organism and of having a significant
underlying gastroduodenal pathology themselves.55,56
If the infected spouse of an index patient is not
treated, there is a high probability that the patient will
be reinfected at a later date and thus exposed to a
greater risk of ulcer recurrence.
Conclusion
Table 3 and the Figure outline the approach we use to
decide whom to test and treat for H pylori infection.
Patients with proven gastric and/or duodenal ulcer
disease and those with early-grade MALT lymphoma
must be given H pylori eradication therapy as the
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first-choice intervention. Proper follow-up to confirm
that eradication and healing have occurred is essen-
tial. Failure to cure the infection is associated with a
high risk of peptic ulcer recurrence, which in turn is
accompanied by the need for further diagnostic
tests, additional medication costs, time lost from work,
and the risk of a life-threatening ulcer complication
(1% annually).15 Maintenance acid suppression is
now outdated and should only be used in exceptional
circumstances. The use of H pylori eradication
therapy in patients with NUD, early gastric cancer, and
post–gastric cancer resection subgroups remains
controversial. Whether or not a course of anti–H pylori
treatment is justified in such patients has to be made
on an individual basis.
Prophylactic anti–H pylori therapy to prevent the
development of gastric cancer or peptic ulcer is not
justified at this stage but preliminary reports suggest
that both gastric cancer42 and peptic ulcer57 prevalences
have been reduced by eliminating the organism. In
addition, the inappropriate use of H pylori eradication
therapy may lead to the appearance of multidrug re-
sistant strains, which are more difficult to eradicate.
For example, it has been shown that in Hong Kong
there was an approximately three-fold increase in the
number of metronidazole-resistant H pylori strains over
5 years (from 1991 to 1995) since the introduction of
metronidazole.58
Although our knowledge and understanding of
the biology, genetics, and virulence of H pylori has
greatly increased over the past decade, there is still
no way of eliminating this organism for good. The
solution will most likely come from the development
of a vaccine such as the one that has been experi-
mentally used in ferrets.59 There are also some pro-
mising vaccine candidates on the horizon.60 A vaccine
would not only help to eradicate the bacterium, but
would also help prevent infection and reinfection.
Table 3. Categories of patients who should and should not be tested for H pylori infection4-6
Yes No
Active peptic ulceration Asymptomatic individuals
Previous peptic ulcer bleeding or perforation Family members of H pylori–positive patients
Confirmed MALT* lymphoma
Following resection of early gastric cancer
Patients with severe NUD†
Previous peptic ulcer history requiring NSAID‡ therapy
Current or recent dyspeptic history requiring long-term NSAID therapy
Spouses of H pylori–positive patients
Patient request after counselling
* MALT mucosa-associated lymphoid tissue†
 NUD non-ulcer dyspepsia‡
 NSAID non-steroidal anti-inflammatory drug
* MALT mucosa-associated lymphoid tissue
Fig. Management algorithm for patients with H pylori–associated pathologies
Test for H pylori
Positive Negative
Eradication therapy Exclude other pathology
Treat symptomatically
H pylori absent H pylori present
Regular follow-up of MALT lymphoma/gastric cancer patients
Reassure others and see on demand
Consider alternative anti–H pylori therapy regimen
Reassess after therapy
Reassess with repeat gastroscopy and biopsy
(for MALT* lymphoma or gastric ulceration)
or with urea C 13 breath test (for duodenal ulceration,
previous ulcer bleeding or perforation, non-ulcer dyspepsia,
or previous early gastric cancer resection)
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